Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02251483 · ClinicalTrials.gov registry record · NA
Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth
A NA study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02251483 is a NA study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT02251483, a NA study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful treatment with rifaximin can lead to more prolonged duration of benefit and delay symptom recurrence. SBI is the main ingredient in EnteraGam™, an orally administered prescription medical food for the dietary management of patients with enteropathy or chronic loose or frequent stools, including patients with IBS-D.
Interventions
- OTHER Placebo
- OTHER Serum-derived bovine immunoglobulin protein isolate (SBI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02251483
The ClinicalTrials.gov registry entry for NCT02251483 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02251483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02251483 about?
NCT02251483 is a clinical study titled "Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth". The primary objective of this study is to determine whether giving SBI as a medical food starting with maintenance of health in the management of chronic loose and frequent stools in IBS-D subjects with SIBO after successful treatment with rifaximin can lead to more prolonged duration of benefit and...
What is the current status of trial NCT02251483?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2014-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02251483?
The interventions under investigation include: Placebo (OTHER), Serum-derived bovine immunoglobulin protein isolate (SBI) (OTHER).
Who is sponsoring clinical trial NCT02251483?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.